Therapeutic opportunities for muscarinic receptors in the central nervous system

Journal of Medicinal Chemistry

Volumn 43, Issue 23, 2000, Pages 4333-4353

  Felder, C C ^a   Bymaster, F P ^a   Ward, J ^a   DeLapp, N ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 BUTYLTHIO 1,2,5 THIADIAZOL 3 YL)QUINUCLIDINE; 3 (6 CHLORO 2 PYRAZINYL)QUINUCLIDINE; 3 [3 (3 METHOXYPHENYL) 2 PROPYNYLOXYIMINO] 1 AZABICYCLO[2.2.1]HEPTANE; ACECLIDINE; ACETYLCHOLINE; ALVAMELINE; ARECOLINE; DARIFENACIN; DIMETINDENE; GALLAMINE; HIMBACINE; METHOCTRAMINE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N [2 (1 AZABICYCLO[3.3.0]OCTAN 5 YL)ETHYL] 2 NITROANILINE FUMARATE; OTENZEPAD; OXOTREMORINE; RECEPTOR SUBTYPE; SABCOMELINE; SECOVERINE; SOLIFENACIN; TALSACLIDINE; THIOPILOCARPINE; TRIPITRAMINE; UNINDEXED DRUG; VAMICAMIDE; VERAPAMIL; VINBURNINE; XANOMELINE;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN STRUCTURE; PSYCHOSIS; RECEPTOR GENE; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ALZHEIMER DISEASE; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; HUMANS; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; PARKINSON DISEASE; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 0034676312     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990607u     Document Type: Review

References (270)

1. Muscarinic receptor subtypes
2. Muscarinic receptors - Characterization, coupling and function
3. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors
4. Muscarinic receptor subtypes and smooth muscle function
5. Molecular biology of muscarinic acetylcholine receptors
6. Muscarinic mechanisms in nerve cells
7. Toxins from mamba venoms: Small proteins with selectivities for different subtypes of muscarinic acetylcholine receptors
8. Muscarinic acetylcholine receptors: Signal transduction through multiple effectors
9. Selective muscarinic receptor agonists and antagonists
10. The pharmacology of flexedil with observations on certain analogues
11. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor
12. Identification of a family of muscarinic acetylcholine receptor genes
13. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes
14. Muscarinic receptor subtypes
15. Projection structure of rhodopsin
16. Crystal structure of rhodopsin: A G protein-coupled receptor
17. The classification of seven transmembrane receptors in recombinant expression systems
18. Structure of rhodopsin
19. Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation
20. The probable arrangement of the helices in G protein-coupled receptors
21. Structure and function of receptors coupled to G proteins
22. Locating ligand-binding sites in 7TM receptors by protein engineering
23. Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors
24. Propylbenzilylcholine mustard labels an acidic residue in transmembrane helix 3 of the muscarinic receptor
25. The role of charge interactions in muscarinic agonist binding, and receptor-response coupling
26. Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists
27. Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants
28. Site-directed mutagenesis of the m3 muscarinic receptor: Identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding
29. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors
30. Muscarinic cholinergic agonists stimulate arachidonic acid release from mouse striatal neurons in primary culture
31. Carbachol-stimulated release of arachidonic acid and eicosanoids from brain cortex synaptoneurosome lipids of adult and aged rats
32. Some evidence against the involvement of arachidonic acid in muscarinic suppression of voltage-gated calcium channel current in guinea-pig ileal smooth muscle cells
33. Stimulation of arachidonic acid release and inhibition of mitogenesis by cloned genes for muscarinic receptor subtypes stably expressed in A9 L cells
34. The ADP-ribosylation factor (ARF)-related GTPase ARF-related protein binds to the ARF-specific guanine nucleotide exchange factor cytohesin and inhibits the ARF-dependent activation of phospholipase D
35. Differential effects of the M1-M5 muscarinic acetylcholine receptor subtypes on intracellular calcium and on the incorporation of choline into membrane lipids in genetically modified Chinese hamster ovary cell lines
36. Muscarinic receptor activated Ca2+ channels in nonexcitable cells
37. Receptor-mediated phospholipase D activity in primary astroglial cultures
38. Coupling of transfected muscarinic acetylcholine receptor subtypes to phospholipase D
39. Cloning and expression of a novel mammalian homologue of Drosophila transient receptor potential (Trp) involved in calcium entry secondary to activation of receptors coupled by the Gq class of G protein
40. Independent induction of morphological transformation of CHO cells by receptor-activated cyclic AMP synthesis or by receptor-operated calcium influx
41. M3 muscarinic receptors mediate an increase in both inositol trisphosphate production and cyclic AMP formation in dog iris sphincter smooth muscle
42. Sensitization of adenylyl cyclase by P2 purinergic and M5 muscarinic receptor agonists in L cells
43. Pharmacological basis for functional selectivity of partial muscarinic receptor agonists
44. A transfected m1 muscarinic acetylcholine receptor stimulates adenylate cyclase via phosphatidylinositol hydrolysis
45. G protein subunits and the stimulation of phospholipase C by Gs- and Gi-coupled receptors: Lack of receptor selectivity of Galpha(16) and evidence for a synergic interaction between Gbeta gamma and the alpha subunit of a receptor activated G protein
46. A transduction pathway associated with receptors coupled to the inhibitory guanine nucleotide binding protein Gi that amplifies ATP-mediated arachidonic acid release
47. Molecular analysis of the regulation of muscarinic receptor expression and function
48. G-protein coupled receptor kinases as modulators of G-protein signaling
49. Signaling pathway leading to an activation of mitogen-activated protein kinase by stimulating M3 muscarinic receptor
50. Receptor protein tyrosine phosphatase alpha participates in the m1 muscarinic acetylcholine receptor-dependent regulation of Kv1.2 channel activity
51. Muscarinic receptor-mediated tyrosine phosphorylation of phospholipase C-gamma. An alternative mechanism for cholinergic-induced phosphoinositide breakdown
52. Activation of transforming G protein-coupled receptors induces rapid tyrosine phosphorylation of cellular proteins, including p125FAK and the p130 v-src substrate
53. A possible role of tyrosine kinases in the regulation of muscarinic receptor-activated cation channels in guinea pig ileum
54. Different effects of muscarinic agonists in rat superior cervical ganglion and hippocampal slices
55. Autoradiographic localization of peripheral M1 muscarinic receptors using [3H]pirenzepine
56. Muscarinic M1 receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens
57. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors
58. Muscarinic M2 and M3 receptor function in smooth muscle
59. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: Distribution of m4 and m5 receptors in rat brain
60. The M5 (m5) receptor subtype: Fact or fiction?
61. Identification and molecular characterization of a m5 muscarinic receptor in A2058 human melanoma cells. Coupling to inhibition of adenylyl cyclase and stimulation of phospholipase A2
62. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice
63. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice
64. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M-4 muscarinic acetylcholine receptor knockout mice
65. Assignment of muscarinic receptor subtypes mediating G-protein modulation of Ca2+ chanels by knockout mice
66. Recent advances in the design and characterization of muscarinic agonists and antagonists
67. Medicinal chemistry of muscarinic agonists: Developments since 1990
68. Synthesis and muscarinic activities of 3-(pyrazolyl)-1,2,5,6-tetrahydropyridine derivatives
69. Pharmacological in vitro characterization of the arecoline bioisostere, Lu 25-109-T, a muscarinic compound with M1-agonist and M2/M3-antagonist properties
70. L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors
71. Pharmacological characterization of the novel cholinomimetic L-689,660 at cloned and native brain muscarinic receptors
72. Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles
73. 3-alkylthio-1,2,5-thiadiazol-1-azabicycles, structure activity relationships for antinociception mediated by central muscarinic receptors
74. Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): A novel analgesic with mixed muscarinic receptor agonist and antagonist activity
75. M1 receptor agonist activity is not a requirement for muscarinic antinociception
76. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane
77. Muscarinic agonists with antipsychotic-like activity: Structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity
78. Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): High throughput assays in mammalian cells
79. Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors
80. Muscarinic agonists. Syntheses and structure-activity relationships of bicyclic isoxazole ester bioisosteres of norarecoline
81. Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine. Synthesis, receptor affinity, and antinociceptive activity
82. Tetrahydropyrimidine derivatives display functional selectivity for M1 muscarinic receptors in brain
83. Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists
84. Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3′-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonist
85. Development of M1 subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy
86. Design of (R(Z))-(+)-alpha-(methoxyimino)-1-azabicyclo(2.2.2)octane-3-acetonitrile (SB-202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere
87. SB 202026: A novel muscarinic partial agonist with functional selectivity for M1 receptors
88. WAL 2014 - A muscarinic agonist with preferential neuron-stimulating properties
89. 6beta-acetoxynortropane: A potent muscarinic agonist with apparent selectivity toward M2-receptors
90. WAY-131256 is an orally active, efficacious, and in vivo functionally selective M1 agonist
91. 1,2,5-thiadiazole analogues of aceclidine as potent m1 muscarinic agonists
92. Synthesis and binding affinity of new muscarinic ligands structurally related to oxotremorine
93. Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans
94. SDZ ENS 163 a novel pilocarpine like drug: Pharmacological in vitro and in vivo profile
95. Workshop: The use of muscarinic toxins in the study of muscarinic receptors
96. Muscarinic toxins from the venom of Dendroaspis snakes with agonist-like actions
97. Clozapine is a potent and selective muscarinic M4 receptor agonist
98. Muscarinic m4 receptor activation by some atypical antipsychotic drugs
99. Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells
100. SR 46559 A and related aminopyridazines are potent muscarinic agonists with no cholinergic syndrome
101. N-[2-(1-Azabicyclo[3.3.0]octan-5-yl)ethyl]-2-nitroanilime, a potent muscarinic agonist
102. Synthesis and muscarinic activity of a series of quinolines and naphthalenes with a 1-azabicyclo[3.3.0]octane moiety
103. A novel structurally unique class of muscarinic agonists
104. Preparation of indanes as antipsychotics
105. M2 receptor binding of the selective antagonist AF-DX 384: Possible involvement of the common allosteric site
106. Characterization of the interaction of zamifenacin at muscarinic receptors in vitro
107. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtypeselective muscarinic receptor antagonists
108. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine
109. Tolterodine - A new bladder-selective antimuscarinic agent
110. Characterization of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors
111. Synthesis and antimuscarinic activity of some 1-cycloalkyl-1-hydroxy-1-phenyl-3-(4-substituted piperazinyl)-2-propanones and related compounds
112. Urinary bladder-selective action of the new antimuscarinic compound vamicamide
113. Novel imidazole derivatives with subtype-selective antimuscarinic activity (1)
114. Novel imidazole derivatives with subtype-selective antimuscarinic activity (2)
115. The (S)-(+)-enantiomer of dimethindene: A novel M2-selective muscarinic receptor antagonist
116. In vitro characterization of a novel, potent and selective M3 antagonist
117. Selectivity of LG50643 for postjunctional muscarinic-receptor subtype in the guinea-pig trachea
118. S-(-)-ET 126: A potent and selective M1 antagonist in vitro and in vivo
119. SAR studies on the potent and selective muscarinic antagonist 2-ethylthio-2,2-diphenylacetic acid N,N-diethylaminoethyl ester
120. Affinity profiles at five cloned human muscarinic receptors (m1-m5) of a new series of antimuscarinic drugs
121. Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9
122. Selective muscarinic antagonists. I. Synthesis and antimuscarinic properties of 4-piperidyl benzhydrylcarbamate derivatives
123. Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenylylcarbamate derivatives
124. 1,2,3,4-tetrahydro-2-isoquinoline carboxylate derivatives: A novel class of selective muscarinic antagonists. III
125. Polymethylene tetraamines: A novel class of cardioselective M2-antagonists
126. Structure-activity relationships and pharmacological profile of selective tricyclic antimuscarinics
127. Design, synthesis, and biological activity of methoctramine-related tetraamines bearing an 11-acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one moiety: Structural requirements for optimum occupancy of muscarinic receptor subtypes as revealed by symmetrical and unsymmetrical polyamines
128. Binding profile of the selective muscarinic receptor antagonist tripitramine
129. The design of novel methoctramine-related tetraamines as muscarinic receptor subtype selective antagonists
130. Universal template approach to drug design: Polyamines as selective muscarinic receptor antagonists
131. Synthesis and biological evaluation of phenylacetyl derivatives having low central nervous system permeability as potent and selective M2 muscarinic receptor antagonists
132. Synthesis of novel succinamide derivatives having a 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one skeleton as potent and selective M2 muscarinic receptor antagonists. II
133. Synthesis of novel succinamide derivatives having the 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one skeleton as potent and selective M2 muscarinic receptor antagonists. I
134. A novel muscarinic receptor ligand which penetrates the blood brain barrier and displays in vivo selectivity for the m2 subtype
135. Discovery of a new class of centrally active M1 selective muscarinic antagonists related to pirenzepine
136. Sila-biperiden and endo-sila-biperiden: Syntheses, crystal structure, and antimuscarinic properties
137. Biological recognition of enantiomeric silanes: Syntheses and antimuscarinic properties of optically active (2-aminoethyl)cyclohexyl(hydroxymethyl)phenylsilanes and related quaternary ammonium derivatives
138. Unsaturated derivatives of the muscarinic antagonists hexahydro-sila- difenidol (HHSiD) and p-fluorohexahydro-sila-difenidol (p-F-HHSiD) with an (E)-Si-CH:CH-CH2-N moiety: Syntheses and binding affinities at muscarinic receptor subtypes
139. Novel alkoxy-oxazolyl-tetrahydropyridine muscarinic cholinergic receptor antagonists
140. Antimuscarinic 3-(2-furanyl)quinuclidin-2-ene derivatives: Synthesis and structure-activity relationships
141. Chemical modification of ring C of himbacine: Discovery of a pharmacephoric element for M2-selectivity
142. Total synthesis of (+)-himbacine and (+)-himbeline
143. Pharmacological characteristics of liriodenine, isolated from Fissistigma glaucescens, a novel muscarinic receptor antagonist in guinea-pigs
144. 3-alpha-chlorimperialine: An M-2-selective muscarinic receptor antagonist that penetrates into brain
145. Identification and characterization of m4 selective muscarinic antagonists
146. Protein toxins that bind to muscarinic acetylcholine receptors
147. A toxin from the green mamba Dendroaspis angusticeps: Amino acid sequence and selectivity for muscarinic m4 receptors
148. Identification of rat brain muscarinic M4 receptors coupled to cyclic AMP using the selective antagonist muscarinic toxin 3
149. Use of antimuscarinic toxins to facilitate studies of striatal m4 muscarinic receptors
150. Allosteric binding sites on muscarinic receptors
151. Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes
152. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors
153. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors
154. Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: Radioligand binding studies
155. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors
156. Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: Identification of a second allosteric site
157. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
158. Anticholinergic psychotomimetic agents
159. Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and anti-parkinson drugs
160. Studies on the relationship of binding affinity to psychoactive and anticholingergic potency of a group of psychotomimetic glycolates
161. Transdermal scopolamine as a cause of transient psychosis in two elderly patients
162. Visual hallucinations on eye closure associated with atropine toxicity. A neurological analysis and comparison with other visual hallucinations
163. Abuse of antiparkinson drugs: A review of the literature
164. Trihexyphenidyl abuse: Therapeutic implications for negative symptoms of schizophrenia?
165. Dopamine receptors and the dopamine hypothesis of schizophrenia
166. Antipsychotic drugs, neurotransmitters, and schizophrenia
167. Acetylcholine treatment of schizophrenia
168. The inhibition of conditional response and counter action of schizophrenia by muscarinic stimulation of the brain
169. Un assai de therapeutique, pathogenique de la schizophrenie par un acetylcholonique l'oxotremorine
170. The effects of physostigmine in phenothiazine resistant chronic schizophrenic patients: Preliminary observations
171. Antagonistic effects of physostigmine and methylphenidate in man
172. A dopaminergic-cholinergic mechanism in the production of psychotic symptoms
173. Influence of noncholinergic drugs on rat striatal acetylcholine levels
174. Elevation of acetylcholine levels in striatum of rat brain by LY163502, trans-(-)-5,5a,6,7,8,9a,10-octahydro-6-propylpyrimido less than 4,5-g greater than quinolin-2-amine dihydrochloride, a potent and stereospecific dopamine (D2) agonist
175. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232)
176. Actions of cocaine on rat dopaminergic neurones in vitro
177. Modulation of dopamine efflux in the nucleus accumbens after cholinergic stimulation of the ventral tegmental area in intact, pedunculopontine tegmental nucleus-lesioned, and laterodorsal tegmental nucleus-lesioned rats
178. On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties
179. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum
180. Differential effects of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats
181. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
182. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain
183. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia
184. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes
185. Muscarinic cholinergic receptors in the rat caudate-putamen and olfactory tubercle belong predominantly to the m4 class: In situ hybridization and receptor autoradiography evidence
186. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia
187. Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: Neuroanatomical and electrophysiological evidence
188. Cholinergic projections to the substantia nigra from the pedunculopontine and laterodorsal tegmental nuclei
189. Cholinergic neurons of the feline pontomesencephalon. II. Ascending anatomical projections
190. Cholinergic input to dopaminergic neurons in the substantia nigra: A double immunocytochemical study
191. The brain stem reticular formation in schizophrenia
192. Cortical cholinergic markers in schizophrenia
193. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies
194. m1-m5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC
195. Muscarinic acetylcholine receptor subtypes: Localization and structure/function
196. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type
197. The cholinergic hypothesis of geriatric memory dysfunction
198. Behavioral disturbance, cognitive dysfunction, and functional skill. Prevalence and relationship in Alzheimer's disease
199. Amyloid deposition as the central event in the aetiology of Alzheimer's disease
200. The molecular pathology of Alzheimer's disease
201. Cellular and molecular biology of Alzheimer's disease and animal models
202. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy
203. From acetylcholine to amyloid: Neurotransmitters and the pathology of Alzheimer's disease
204. Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey
205. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase
206. Differential cholinergic innervation within functional subdivisions of the human cerebral cortex: A choline acetyltransferase study
207. Topography of the magnocellular basal forebrain system in human brain
208. Memory-related neural systems in Alzheimer's disease: An anatomic study
209. Immunocytochemical distribution of peptidergic and cholinergic fibers in the human amygdala: Their depletion in Alzheimer's disease and morphologic alteration in nondemented elderly with numerous senile plaques
210. Cholinergic innervation of the amygdaloid complex in the human brain and its alterations in old age and Alzheimer's disease
211. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex
212. The synaptic organization of the neocortex in Alzheimer's disease
213. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia
214. Selective loss of central cholinergic neurons in Alzheimer's disease
215. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
216. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease
217. Choline acetyltransferase immunohistochemistry in brains of Alzheimer's disease patients and controls
218. Alzheimer's disease: A disorder of cortical cholinergic innervation
219. Neurechemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits
220. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications
221. Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease
222. Pharmacological drug treatment of Alzheimer disease: The cholinergic hypothesis revisited
223. Muscarinic receptor agonists in Alzheimer's disease more than just symptomatic treatment?
224. Learning and memory deficits after lesions of the nucleus basalis magnocellularis: Reversal by physostigmine
225. Physostigmine improves water maze performance following nucleus basalis magnocellularis lesions in rats
226. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat
227. AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat
228. Rats with nucleus basalis magnocellularis lesions mimic mnemonic symptomatology observed in patients with dementia of the Alzheimer's type
229. Nucleus basalis lesions: Implication of basoamygdaloid cholinergic pathways in memory
230. Essential role of neocortical acetylcholine in spatial memory
231. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study
232. Tacrine in Alzheimer's disease
233. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering?
234. Perspectives in the management of Alzheimer's disease: Clinical profile of donepezil
235. Physostigmine: Improvement of long-term memory processes in normal humans
236. Long-term administration of oral physostigmine in Alzheimer's disease
237. Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease
238. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats
239. Effects of disrupting the cholinergic system on short-term spatial memory in rats
240. Blockade of hippocampal M1 muscarinic receptors impairs working memory performance of rats
241. Cholinergic receptor agonists inhibit pirenzepine-induced dysfunction of spontaneous alternation performance in the mouse
242. Human memory and the cholinergic system. A relationship to aging?
243. Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease
244. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells
245. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation
246. Intraventricular bethanechol infusion for Alzheimer's disease: Results of double-blind and escalating-dose trials
247. Multiple-dose arecoline infusions in Alzheimer's disease
248. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease
249. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain
250. Cholinergic and serotonergic stimulation of phosphoinositide hydrolysis is decreased in Alzheimer's disease
251. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease
252. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: Differential sensitivity to agonists and divalent cations
253. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
254. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein
255. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells
256. Regulated secretion of beta-amyloid precursor protein in rat brain
257. Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions
258. In vivo regulation of amyloid precursor protein secretion in rat neocortex by cholinergic activity
259. Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells
260. Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment
261. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology
262. Cholinergic-anticholinergic antagonism in parkinsonism
263. Preliminary report: Intracranial cholinergic drug infusion in patients with Alzheimer's disease
264. Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism
265. Exacerbation of parkinsonism by tacrine
266. Tacrine: A pharmacological approach to Alzheimer's disease
267. Uniform frequency of parkinsonian resting tremor in the lips, jaw, tongue, and index finger
268. Characterization of the muscarinic receptor subtype mediating pilocarpine-induced tremulous jaw movements in rats
269. Tremulous jaw movements in rats: A model of parkinsonian tremor
270. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis